Publicacións nas que colabora con Domingo Andrés Pascual Figal (77)

2024

  1. Diagnosis and treatment of myocarditis and inflammatory cardiomyopathy. Consensus document of the SEC-Working Group on Myocarditis

    Revista Espanola de Cardiologia

2023

  1. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  2. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  3. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

  4. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial

    The Lancet, Vol. 402, Núm. 10396, pp. 118-128

2022

  1. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

    Circulation, Vol. 146, Núm. 16, pp. 1196-1206

  2. Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice

    Revista Española de Cardiología (English Edition), Vol. 75, Núm. 5, pp. 364-369

  3. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

    The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45

  4. Environmental factors like air pollution: not to be forgotten in the 2021 ESC guidelines on heart failure. Response

    Revista Espanola de Cardiologia

  5. Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics

    Journal of Clinical Medicine, Vol. 11, Núm. 5

  6. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

  7. Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure

    Frontiers in Cardiovascular Medicine, Vol. 9

  8. Serum potassium dynamics during acute heart failure hospitalization

    Clinical Research in Cardiology, Vol. 111, Núm. 4, pp. 368-379

2021

  1. A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure

    Frontiers in Physiology, Vol. 12

  2. Ischemic etiology and prognosis in men and women with acute heart failure

    Journal of Clinical Medicine, Vol. 10, Núm. 8

  3. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review

    Frontiers in Cardiovascular Medicine, Vol. 8

  4. Spanish Heart Transplant Registry. 32nd Official Report of the Heart Failure Association of the Spanish Society of Cardiology

    Revista Espanola de Cardiologia, Vol. 74, Núm. 11, pp. 962-970

2020

  1. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain

    Revista Espanola de Cardiologia, Vol. 73, Núm. 5, pp. 361-367

  2. Expert consensus statement on heart failure with reduced ejection fraction: beyond the guidelines

    Revista Espanola de Cardiologia Suplementos, Vol. 20, Núm. SB, pp. 1-46

  3. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 4, pp. 313-323